Fazeli Dehkordy, Soudabeh
Fowler, Kathryn J.
Wolfson, Tanya
Igarashi, Saya
Lamas Constantino, Carolina P.
Hooker, Jonathan C.
Hong, Cheng W.
Mamidipalli, Adrija
Gamst, Anthony C.
Hemming, Alan
Sirlin, Claude B.
Funding for this research was provided by:
National Institutes of Health (T32 EB005970-09)
Article History
First Online: 31 October 2017
Compliance with ethical standards
:
: National Institutes of Health Grant T32 EB005970-09.
: SFD was supported by a T32 Grant from the NIH (4T32EB005970-09) at the time of the study. KF declares that she has no conflict of interest. TW declares that she has no conflict of interest. SI declares that she has no conflict of interest. CLP declares that she has no conflict of interest. JH declares that he has no conflict of interest. CH declares that he has no conflict of interest. AM declares that she has no conflict of interest. AG declares that he has no conflict of interest. AH declares that he has no conflict of interest. CS has received research grants from Siemens, GE, and Guerbet. CS also consults and advises for Alexion, AstraZeneca, Bioclinica, BMS, Fibrogen, Galmed, Genzyme, Gilead, Fibrogen, Icon, Intercept, Isis, Janssen, NuSirt, Perspectum, Pfizer, Profil, Sanofi, Shire, Synageva, Tobira, Takeda, Virtual Scopics.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Due to retrospective and observational nature of our study, patient consent was not required by the IRB.